Lilly’s Alzheimer’s drug shows 60% decrease in mild impairment during clinical trial

JUST IN: Lilly’s Donanemab Slows Alzheimer’s Progression by 60% in Mildly Impaired Patients, Study Finds. Promising results for Eli Lilly’s experimental drug, donanemab! It has shown a 60% slowdown in Alzheimer’s disease progression among patients in the earliest stages. Early detection and diagnosis are key in altering the trajectory of this devastating disease. Read more about the study below. #TheReportify #Alzheimersresearch #HealthNews Remember to share your thoughts in the comments below! https://thereportify.com/lillys-alzheimers-drug-shows-60-decrease-in-mild-impairment-during-clinical-trial/